Page last updated: 2024-08-24

aripiprazole and Metabolic Diseases

aripiprazole has been researched along with Metabolic Diseases in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (41.67)	29.6817
2010's	7 (58.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT	1
Dai, G; Zhang, Y	1
Alshehabi, E; Rickels, K; Rickels, MR; Teff, KL	1
Alonso-Martín, C; Arias-Loste, MT; Crespo, J; Crespo-Facorro, B; Fábrega, E; Martínez-García, O; Morlán-Coarasa, MJ; Ortiz-García de la Foz, V; Romero-Gómez, M	1
Baker, RA; Berman, RM; Fava, M; Marcus, RN; Pikalov, A; Thase, ME; Tran, QV; Wisniewski, SR; Yang, H	1
McIntyre, RS	2
Eriksson, J; Kasteng, F; Lindgren, P; Sennfält, K	1
Bobmanuel, S; Davies, W; Dratcu, L; Farmer, A; George, M; Rana, T; Singh, M; Turner, M	1
Burns, T; Dursun, S; Fahy, T; Frangou, S; Gray, R; Haddad, PM; Hunter, R; Taylor, DM; Travis, MJ; Young, AH	1
Chavez, B; Poveda, RA	1
Chen, CH; Huang, MC; Lu, ML	1

Reviews

2 review(s) available for aripiprazole and Metabolic Diseases

Article	Year
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Biomarkers; Blood Glucose; Body Mass Index; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Lipid Metabolism; Lipids; Logistic Models; Male; Metabolic Diseases; Middle Aged; Multicenter Studies as Topic; Obesity; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult	2009
Aripiprazole for the maintenance treatment of bipolar I disorder: A review. Clinical therapeutics, 2010, Volume: 32 Suppl 1 Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Humans; Lithium; Metabolic Diseases; Obesity; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome	2010

Article

Year

Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.

Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4

Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Biomarkers; Blood Glucose; Body Mass Index; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Lipid Metabolism; Lipids; Logistic Models; Male; Metabolic Diseases; Middle Aged; Multicenter Studies as Topic; Obesity; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult

2009

Aripiprazole for the maintenance treatment of bipolar I disorder: A review.

Clinical therapeutics, 2010, Volume: 32 Suppl 1

Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Humans; Lithium; Metabolic Diseases; Obesity; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome

2010

Trials

2 trial(s) available for aripiprazole and Metabolic Diseases

Article	Year
Efﬁcacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Human psychopharmacology, 2012, Volume: 27, Issue:6 Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult	2012
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology, 2016, Volume: 233, Issue:23-24 Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Middle Aged; Non-alcoholic Fatty Liver Disease; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult	2016

Article

Year

Efﬁcacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.

Human psychopharmacology, 2012, Volume: 27, Issue:6

Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult

2012

Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.

Psychopharmacology, 2016, Volume: 233, Issue:23-24

Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Middle Aged; Non-alcoholic Fatty Liver Disease; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult

2016

Other Studies

8 other study(ies) available for aripiprazole and Metabolic Diseases

Article	Year
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. Journal of medicinal chemistry, 2007, Oct-18, Volume: 50, Issue:21 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain	2007
Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Ghrelin; Humans; Hunger; Leptin; Metabolic Diseases; Olanzapine; Postprandial Period; Satiety Response; Time Factors	2015
The role of aripiprazole in Canada: A review of clinical and drug discontinuation data. Foreword. Clinical therapeutics, 2010, Volume: 32 Suppl 1 Topics: Antipsychotic Agents; Aripiprazole; Canada; Clinical Trials as Topic; Comorbidity; Drug Utilization; Drug Utilization Review; Humans; Metabolic Diseases; Mood Disorders; Piperazines; Psychotic Disorders; Quinolones; Risk Factors	2010
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta psychiatrica Scandinavica, 2011, Volume: 124, Issue:3 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Coronary Disease; Costs and Cost Analysis; Female; Humans; Male; Metabolic Diseases; Metabolism; Middle Aged; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quinolones; Risk Assessment; Schizophrenia; Sweden	2011
A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania. International journal of psychiatry in clinical practice, 2012, Volume: 16, Issue:4 Topics: Acute Disease; Anhedonia; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Combination; Humans; Long-Term Care; Metabolic Diseases; Patient Participation; Piperazines; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Sexual Dysfunction, Physiological; Treatment Outcome	2012
Aripiprazole in schizophrenia: consensus guidelines. International journal of clinical practice, 2005, Volume: 59, Issue:4 Topics: Antipsychotic Agents; Aripiprazole; Consensus; Drug Interactions; Heart Diseases; Humans; Hypertension; Mental Disorders; Metabolic Diseases; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Treatment Outcome	2005
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances. The Annals of pharmacotherapy, 2006, Volume: 40, Issue:12 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Humans; Male; Metabolic Diseases; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain	2006
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Male; Metabolic Diseases; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain	2007